drugset / Trial / NCT06752447
A Phase I Study OfLNF2007 Monotherapy in Patients with Advanced Solid Tumors
Non-randomizedSingle-groupOpen-labelTreatment
Summary
A non-randomized, open-ended, phase I dose-escalation and dose-expansion study was designed to evaluate the safety, tolerability, antitumor efficacy, PK and immunogenic characteristics of LNF2007 in patients with advanced solid tumors
Timeline
- Start
- 2025-01-20
- Primary completion
- 2026-12
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LNF2007 | Unknown | 0.2 ug/kg | Intravenous |
| Subject | LNF2007 | Unknown | 1 ug/kg | Intravenous |
| Subject | LNF2007 | Unknown | 5 ug/kg | Intravenous |
| Subject | LNF2007 | Unknown | 20 ug/kg | Intravenous |
| Subject | LNF2007 | Unknown | 60 ug/kg | Intravenous |
| Subject | LNF2007 | Unknown | 120 ug/kg | Intravenous |
| Subject | LNF2007 | Unknown | 240 ug/kg | Intravenous |
| Subject | LNF2007 | Unknown | 360 ug/kg | Intravenous |
| Subject | LNF2007 | Unknown | 540 ug/kg | Intravenous |
Indications
No indication recorded.